Table 2:
Common Treatment Regimens Received at Cycle One
| Treatment regimen | All patients (N=718) | GA arm (N=349) | Usual care arm (N=369) |
|---|---|---|---|
| Lung cancer regimens | N=180 | N=64 | N= 116 |
| Pemetrexed- carboplatin +/− pembrolizumab | 66 (36%) | 13 (20%) | 53 (46%) |
| Paclitaxel- carboplatin +/− monoclonal antibody | 36 (20%) | 20 (30%) | 16 (14%) |
| Carboplatin- etoposide | 20 (10%) | 5 (8%) | 15 (13%) |
| Carboplatin- nab paclitaxel | 17 (9%) | 7 (11%) | 10 (9%) |
| Gastro-intestinal cancers regimens | N=246 | N=132 | N= 114 |
| FOLFOX +/− bevacizumab | 65 (26%) | 25 (19%) | 40 (35%) |
| Gemcitabine- nab paclitaxel | 44 (18%) | 24 (18%) | 20 (18%) |
| Capecitabine | 23 (9%) | 21(16%) | 2 (2%) |
| FOLFIRI +/− bevacizumab | 18 (7%) | 12 (9%) | 6 (5%) |
| FOLFIRINOX +/− bevacizumab | 9 (4%) | 3 (2%) | 6 (5%) |
| Genito-urinary cancers regimens | N=109 | N=56 | N= 53 |
| Abiraterone +/− prednisone | 35 (32%) | 22 (39%) | 13 (25%) |
| Docetaxel +/− prednisone | 32 (29%) | 19 (34%) | 13 (25%) |
| Enzalutamide +/− prednisone | 13 (12%) | 3 (5%) | 10 (19%) |
| Gemcitabine carboplatin | 11 (10%) | 3 (5%) | 8 (15%) |
| Breast Cancer regimens | N= 56 | N= 19 | N= 37 |
| Palbociclib+ AI | 18 (32%) | 6 (32%) | 12 (32%) |
| Paclitaxel +/− trastuzumab | 8 (14%) | 1 (5%) | 8 (22%) |
| Gemcitabine carboplatin +/− trastuzumab | 5 (9%) | 2 (11%) | 3 (8%) |
| Capecitabine | 4 (7%) | 0 (0%) | 4 (11%) |
| Lymphoma Regimens | N=46 | N=23 | N= 23 |
| BR | 18 (39%) | 7 (30%) | 11(48%) |
| R-CHOP | 9 (20%) | 5 (22%) | 4(17%) |
| Gynecological cancers regimens | N=43 | N=29 | N= 14 |
| Paclitaxel carboplatin | 19 (44%) | 10 (35%) | 9 (60%) |
*
This table only included commonly received regimens at cycle one
Abbreviations: AI, aromatase inhibitors; BR, bendamustine/rituximab; FOLOFOX, 5-fluorouracil/ leucovorin/ oxaliplatin; FOLFIRI, 5-fluorouracil/ leucovorin/ irinotecan; FOLFIRINOX/ 5-fluorouracil/ leucovorin/ oxaliplatin/ irinotecan; R-CHOP, rituximab/ cyclophosphamide/ doxorubicin/ prednisone/ vincristine